First Manhattan
VYNE icon

First Manhattan’s VYNE Therapeutics VYNE Stock Holding History

First Manhattan’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-142
Closed -$383 – 1713
2022
Q4 		$383 Hold
142
– – ﹤0.01% 1619
2022
Q3 		$0 Hold
142
– – ﹤0.01% 1665
2022
Q2 		$0 Hold
142
– – ﹤0.01% 1680
2022
Q1 		$1K Hold
142
– – ﹤0.01% 1564
2021
Q4 		$2K Hold
142
– – ﹤0.01% 1494
2021
Q3 		$3K Sell
142
-154
-52% -$5.97K ﹤0.01% 1498
2021
Q2 		$18K Hold
296
– – ﹤0.01% 1178
2021
Q1 		$36K Hold
296
– – ﹤0.01% 1028
2020
Q4 		$33K Sell
296
-42
-12% -$5.28K ﹤0.01% 975
2020
Q3 		$40K Sell
338
-304
-47% -$35.5K ﹤0.01% 916
2020
Q2 		$79K Buy
+642
New +$86.9K ﹤0.01% 811
2020
Q1 		– Sell
-30,111
Closed -$10.1M – 1466
2019
Q4 		$10.1M Sell
30,111
-73
-0.2% -$24.3K 0.05% 166
2019
Q3 		$9.74M Sell
30,184
-735
-2% -$237K 0.05% 166
2019
Q2 		$13.3M Sell
30,919
-427
-1% -$211K 0.07% 137
2019
Q1 		$17.7M Buy
31,346
+12,938
+70% +$6.21M 0.1% 112
2018
Q4 		$5.46M Buy
18,408
+5,258
+40% +$2.35M 0.03% 228
2018
Q3 		$9.33M Buy
13,150
+12,726
+3,001% +$7.86M 0.05% 196
2018
Q2 		$248K Buy
+424
New +$330K ﹤0.01% 660

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

First Manhattan's VYNE Position: Q1 2023 in Review

First Manhattan sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 142 shares — an estimated $383 sold.

First Manhattan first reported a position in VYNE in Q2 2018 and held it in 18 quarters. The position peaked at $17.7M in Q1 2019. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • First Manhattan reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • First Manhattan sold 142 VYNE Therapeutics shares in Q1 2023, an estimated $383.
  • First Manhattan first reported a position in VYNE Therapeutics in Q2 2018 and held it in 18 quarters.
  • First Manhattan's VYNE Therapeutics position peaked at $17.7M in Q1 2019.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.